In this interview from the ARVO 2013 Annual Meeting, Dr. Simon Harding shares two-year results from the Inhibit VEGF in Age-related Choroidal Neovascularization (IVAN) trial. Similar to the Comparison of AMD Treatment Trials (CATT), IVAN was designed to compare ranibizumab and bevacizumab and different regimens. He tells Dr. Daniel Martin that the two drugs appear to have similar efficacy, and that monthly administration may offer some advantages over as-needed treatment. Additionally, safety was worse when treatment was administered as-needed. These findings highlight that the choice of anti-VEGF treatment strategy is less straightforward than previously thought.